M1-aminopeptidase family — beyond antigen-trimming activities

IF 6.6 2区医学 Q1 IMMUNOLOGY Current Opinion in Immunology Pub Date : 2023-08-01 DOI:10.1016/j.coi.2023.102337

Irini Evnouchidou , Despoina Koumantou , Mathilde Nugue , Loredana Saveanu

{"title":"M1-aminopeptidase family — beyond antigen-trimming activities","authors":"Irini Evnouchidou , Despoina Koumantou , Mathilde Nugue , Loredana Saveanu","doi":"10.1016/j.coi.2023.102337","DOIUrl":null,"url":null,"abstract":"<div><p>Antigen (Ag)-trimming aminopeptidases belong to the oxytocinase subfamily of M1 metallopeptidases. In humans, this subfamily contains the endoplasmic reticulum aminopeptidases 1 and 2 (ERAP1 and 2) and the insulin-responsive aminopeptidase (IRAP, synonym oxytocinase), an endosomal enzyme. The ability of these enzymes to trim antigenic precursors and to generate major histocompatibility class-I ligands has been demonstrated extensively for ERAP1, less for ERAP2, which is absent in rodents, and exclusively in the context of cross-presentation for IRAP. During 20 years of research on these aminopeptidases, their enzymatic function has been very well characterized and their genetic association with autoimmune diseases, cancers, and infections is well established. The mechanisms by which these proteins are associated to human diseases are not always clear. This review discusses the Ag-trimming-independent functions of the oxytocinase subfamily of M1 aminopeptidases and the new questions raised by recent publications on IRAP and ERAP2.</p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"83 ","pages":"Article 102337"},"PeriodicalIF":6.6000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0952791523000560","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Antigen (Ag)-trimming aminopeptidases belong to the oxytocinase subfamily of M1 metallopeptidases. In humans, this subfamily contains the endoplasmic reticulum aminopeptidases 1 and 2 (ERAP1 and 2) and the insulin-responsive aminopeptidase (IRAP, synonym oxytocinase), an endosomal enzyme. The ability of these enzymes to trim antigenic precursors and to generate major histocompatibility class-I ligands has been demonstrated extensively for ERAP1, less for ERAP2, which is absent in rodents, and exclusively in the context of cross-presentation for IRAP. During 20 years of research on these aminopeptidases, their enzymatic function has been very well characterized and their genetic association with autoimmune diseases, cancers, and infections is well established. The mechanisms by which these proteins are associated to human diseases are not always clear. This review discusses the Ag-trimming-independent functions of the oxytocinase subfamily of M1 aminopeptidases and the new questions raised by recent publications on IRAP and ERAP2.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

M1氨肽酶家族——超越抗原修饰活性

抗原修饰氨基肽酶属于M1金属肽酶的催产素酶亚家族。在人类中，该亚家族包含内质网氨肽酶1和2（ERAP1和2）以及胰岛素反应性氨肽酶（IRAP，同义词催产素酶），一种内体酶。这些酶修饰抗原前体和产生主要组织相容性I类配体的能力已被广泛证明适用于ERAP1，较少适用于啮齿类动物中不存在的ERAP2，并且仅在IRAP的交叉呈递背景下。在对这些氨肽酶20年的研究中，它们的酶功能已经得到了很好的表征，并且它们与自身免疫性疾病、癌症和感染的遗传联系也得到了很强的证实。这些蛋白质与人类疾病相关的机制并不总是清楚的。这篇综述讨论了M1氨肽酶的催产素酶亚家族的Ag修剪非依赖性功能，以及最近关于IRAP和ERAP2的出版物提出的新问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Opinion in Immunology 医学-免疫学

CiteScore

13.30

自引率

1.40%

发文量

审稿时长

67 days

期刊介绍： Current Opinion in Immunology aims to stimulate scientifically grounded, interdisciplinary, multi-scale debate and exchange of ideas. It contains polished, concise and timely reviews and opinions, with particular emphasis on those articles published in the past two years. In addition to describing recent trends, the authors are encouraged to give their subjective opinion of the topics discussed. In Current Opinion in Immunology we help the reader by providing in a systematic manner: 1. The views of experts on current advances in their field in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications. Current Opinion in Immunology will serve as an invaluable source of information for researchers, lecturers, teachers, professionals, policy makers and students. Current Opinion in Immunology builds on Elsevier''s reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. It is a companion to the new Gold Open Access journal Current Research in Immunology and is part of the Current Opinion and Research(CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists'' workflow.